216 related articles for article (PubMed ID: 27876659)
1. Surgical Treatment for Patients with Moyamoya Syndrome and Type 1 Neurofibromatosis.
Porras JL; Yang W; Garzon-Muvdi T; Xu R; Blakeley J; Belzberg A; Caplan JM; Khalid S; Colby GP; Coon AL; Tamargo RJ; Ahn ES; Huang J
World Neurosurg; 2017 Mar; 99():19-25. PubMed ID: 27876659
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of surgical revascularization for stroke prevention in pediatric patients with sickle cell disease and moyamoya syndrome.
Yang W; Xu R; Porras JL; Takemoto CM; Khalid S; Garzon-Muvdi T; Caplan JM; Colby GP; Coon AL; Tamargo RJ; Huang J; Ahn ES
J Neurosurg Pediatr; 2017 Sep; 20(3):232-238. PubMed ID: 28686127
[TBL] [Abstract][Full Text] [Related]
3. Moyamoya syndrome associated with neurofibromatosis Type 1: perioperative and long-term outcome after surgical revascularization.
Koss M; Scott RM; Irons MB; Smith ER; Ullrich NJ
J Neurosurg Pediatr; 2013 Apr; 11(4):417-25. PubMed ID: 23373626
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and long-term outcomes of moyamoya syndrome associated with neurofibromatosis type 1.
Han C; Yang WZ; Zhang HT; Ye T; Duan L
J Clin Neurosci; 2015 Feb; 22(2):286-90. PubMed ID: 25443089
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome in children with moyamoya syndrome after cranial revascularization by pial synangiosis.
Scott RM; Smith JL; Robertson RL; Madsen JR; Soriano SG; Rockoff MA
J Neurosurg; 2004 Feb; 100(2 Suppl Pediatrics):142-9. PubMed ID: 14758941
[TBL] [Abstract][Full Text] [Related]
6. Down syndrome and moyamoya: clinical presentation and surgical management.
See AP; Ropper AE; Underberg DL; Robertson RL; Scott RM; Smith ER
J Neurosurg Pediatr; 2015 Jul; 16(1):58-63. PubMed ID: 25837890
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Moyamoya disease in the adult population with pial synangiosis.
Lin N; Aronson JP; Manjila S; Smith ER; Scott RM
J Neurosurg; 2014 Mar; 120(3):612-7. PubMed ID: 24405066
[TBL] [Abstract][Full Text] [Related]
8. Distinct Clinical and Radiographic Phenotypes in Pediatric Patients With Moyamoya.
Kaseka ML; Slim M; Muthusami P; Dirks PB; Westmacott R; Kassner A; Bhathal I; Williams S; Shroff M; Logan W; Moharir M; MacGregor DL; Pulcine E; deVeber GA; Dlamini N
Pediatr Neurol; 2021 Jul; 120():18-26. PubMed ID: 33962345
[TBL] [Abstract][Full Text] [Related]
9. Pial synangiosis in patients with moyamoya syndrome and sickle cell anemia: perioperative management and surgical outcome.
Smith ER; McClain CD; Heeney M; Scott RM
Neurosurg Focus; 2009 Apr; 26(4):E10. PubMed ID: 19335126
[TBL] [Abstract][Full Text] [Related]
10. Surgical revascularization as a procedure to prevent neurological complications in children with moyamoya syndrome associated with neurofibromatosis I: a single institution case series.
Morello A; Scala M; Schiavetti I; Diana MC; Severino M; Tortora D; Piatelli G; Pavanello M
Childs Nerv Syst; 2024 Jun; 40(6):1731-1741. PubMed ID: 38316674
[TBL] [Abstract][Full Text] [Related]
11. 'Moya' than meets the eye: neurofibromatosis type 1 associated with Moyamoya syndrome.
Tan RM; Chng SM; Seow WT; Wong J; Lim CC
Singapore Med J; 2008 Apr; 49(4):e107-9. PubMed ID: 18418511
[TBL] [Abstract][Full Text] [Related]
12. Moyamoya syndrome associated with Down syndrome: outcome after surgical revascularization.
Jea A; Smith ER; Robertson R; Scott RM
Pediatrics; 2005 Nov; 116(5):e694-701. PubMed ID: 16263984
[TBL] [Abstract][Full Text] [Related]
13. Outcome of repeat revascularization surgery for moyamoya disease after an unsuccessful indirect revascularization. Clinical article.
Pandey P; Steinberg GK
J Neurosurg; 2011 Aug; 115(2):328-36. PubMed ID: 21529138
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Ipsilateral Stroke Prevention Between Conservative Management and Indirect Revascularization for Moyamoya Disease in a North American Cohort.
Porras JL; Yang W; Xu R; Garzon-Muvdi T; Caplan JM; Colby GP; Coon AL; Ahn ES; Tamargo RJ; Huang J
World Neurosurg; 2018 Feb; 110():e928-e936. PubMed ID: 29196251
[TBL] [Abstract][Full Text] [Related]
15. Cerebral Revascularization for Moyamoya Syndrome Associated with Sickle Cell Disease: A Systematic Review of the Literature on the Role of Extracranial-Intracranial Bypass in Treating Neurologic Manifestations of Pediatric Patients with Sickle Cell Disease.
Terrell D; Savardekar AR; Whipple SG; Dossani RH; Spetzler RF; Sun H
World Neurosurg; 2020 May; 137():62-70. PubMed ID: 32014541
[TBL] [Abstract][Full Text] [Related]
16. Pial synangiosis in patients with moyamoya younger than 2 years of age.
Jackson EM; Lin N; Manjila S; Scott RM; Smith ER
J Neurosurg Pediatr; 2014 Apr; 13(4):420-5. PubMed ID: 24527861
[TBL] [Abstract][Full Text] [Related]
17. Revascularization of Moyamoya Angiopathy in Older Adults.
Williamson RW; Abla AA; Zabramski JM; Nakaji P; Spetzler RF; Wanebo JE
World Neurosurg; 2017 Mar; 99():37-40. PubMed ID: 27890765
[TBL] [Abstract][Full Text] [Related]
18. The importance of encephalo-myo-synangiosis in surgical revascularization strategies for moyamoya disease in children and adults.
Imai H; Miyawaki S; Ono H; Nakatomi H; Yoshimoto Y; Saito N
World Neurosurg; 2015 May; 83(5):691-9. PubMed ID: 25655688
[TBL] [Abstract][Full Text] [Related]
19. Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease.
Griessenauer CJ; Lebensburger JD; Chua MH; Fisher WS; Hilliard L; Bemrich-Stolz CJ; Howard TH; Johnston JM
J Neurosurg Pediatr; 2015 Jul; 16(1):64-73. PubMed ID: 25837886
[TBL] [Abstract][Full Text] [Related]
20. Surgical outcomes following encephaloduroarteriosynangiosis in North American adults with moyamoya.
Agarwalla PK; Stapleton CJ; Phillips MT; Walcott BP; Venteicher AS; Ogilvy CS
J Neurosurg; 2014 Dec; 121(6):1394-400. PubMed ID: 25280094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
